Secrets of spironolactone: continuing insights from TOPCAT Americas

Eur J Heart Fail. 2020 Sep;22(9):1625-1627. doi: 10.1002/ejhf.1959. Epub 2020 Aug 5.

Authors

Andreas P Kalogeropoulos¹, Panagiotis Simitsis², Hal A Skopicki¹

Affiliations

¹ Division of Cardiology, Department of Medicine, Stony Brook University, Stony Brook, NY, USA.
² Heart Failure Unit, Departments of Cardiology & Critical Care Medicine, Attikon University Hospital, University of Athens Medical School, Athens, Greece.

PMID: 32628354
DOI: 10.1002/ejhf.1959

No abstract available

Publication types

Editorial
Comment

MeSH terms

Americas
Heart Failure* / drug therapy
Heart Failure* / epidemiology
Humans
Mineralocorticoid Receptor Antagonists
Spironolactone*
Stroke Volume

Substances

Mineralocorticoid Receptor Antagonists
Spironolactone